Mitochondria1 Abnormalities of Liver in Primary Ornithine Transcarbamylase Deficiency
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Raised Intracranial Pressure and Hydrocephalus
Raised Intracranial Pressure and Hydrocephalus Sept 2014 Raised Intracranial Pressure 500ml/day CSF made to replenish volume of 150ml. ICP = MAP-CPP. Normal ~10mmHg. Raised = >20mmHg sustained for >15min. ICP monitoring if severe HI & coma, intracerebral haemorrhage, Reye’s, hydrocephalus Causes of raised intracranial pressure Localised mass lesions: traumatic haematomas (extradural, subdural, intracerebral) Neoplasms: glioma, meningioma, metastasis Abscess Focal oedema secondary to trauma, infarction, tumour Disturbance of CSF circulation: obstructive hydrocephalus, communicating hydrocephalus Obstruction to venous sinuses: depressed fractures overlying venous sinuses, cerebral venous thrombosis Diffuse brain oedema or swelling: encephalitis, meningitis, diffuse head injury, SAH, Reye's syndrome, lead encephalopathy, water intoxication, near drowning Idiopathic intracranial hypertension Presentation Headache: nocturnal, on waking, worse on coughing/moving head ↓LOC: lethargy, irritability, slow decision making, abnormal behaviour → stupor, coma and death Vomiting Eye changes: irregularity or dilatation in one eye. Unilateral ptosis or III and VI nerve palsies. In later stages, ophthalmoplegia and loss of vestibulo-ocular reflexes. Papilloedema: blurring of disc margins, loss of venous pulsations, disc hyperaemia, flame haemorrhages. Later, obscured disc margins and retinal haemorrhages. Cushing reflex: ( ↑BP, widened pulse pressure and ↓HR). Other: Late hemiparesis Investigations CT/MRI Check and monitor ABG, blood glucose, renal function, -
The Regulation of Carbamoyl Phosphate Synthetase-Aspartate Transcarbamoylase-Dihydroorotase (Cad) by Phosphorylation and Protein-Protein Interactions
THE REGULATION OF CARBAMOYL PHOSPHATE SYNTHETASE-ASPARTATE TRANSCARBAMOYLASE-DIHYDROOROTASE (CAD) BY PHOSPHORYLATION AND PROTEIN-PROTEIN INTERACTIONS Eric M. Wauson A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Pharmacology. Chapel Hill 2007 Approved by: Lee M. Graves, Ph.D. T. Kendall Harden, Ph.D. Gary L. Johnson, Ph.D. Aziz Sancar M.D., Ph.D. Beverly S. Mitchell, M.D. 2007 Eric M. Wauson ALL RIGHTS RESERVED ii ABSTRACT Eric M. Wauson: The Regulation of Carbamoyl Phosphate Synthetase-Aspartate Transcarbamoylase-Dihydroorotase (CAD) by Phosphorylation and Protein-Protein Interactions (Under the direction of Lee M. Graves, Ph.D.) Pyrimidines have many important roles in cellular physiology, as they are used in the formation of DNA, RNA, phospholipids, and pyrimidine sugars. The first rate- limiting step in the de novo pyrimidine synthesis pathway is catalyzed by the carbamoyl phosphate synthetase II (CPSase II) part of the multienzymatic complex Carbamoyl phosphate synthetase, Aspartate transcarbamoylase, Dihydroorotase (CAD). CAD gene induction is highly correlated to cell proliferation. Additionally, CAD is allosterically inhibited or activated by uridine triphosphate (UTP) or phosphoribosyl pyrophosphate (PRPP), respectively. The phosphorylation of CAD by PKA and ERK has been reported to modulate the response of CAD to allosteric modulators. While there has been much speculation on the identity of CAD phosphorylation sites, no definitive identification of in vivo CAD phosphorylation sites has been performed. Therefore, we sought to determine the specific CAD residues phosphorylated by ERK and PKA in intact cells. -
Reye's Syndrome Difficult Its 32A, 381
662 BRITISH MEDICAL JOURNAL 20 SEPTEMBER 1975 5 Dwyer, A. F., Newton, N. C., and Sherwood, A. A., Clinical Orthopaedics amino-acid pattern.7 Confirmation of the diagnosis requires and Related Research, 1969, 62, 192. Br Med J: first published as 10.1136/bmj.3.5985.662 on 20 September 1975. Downloaded from 6 Dewald, R. L., and Ray, R. D., Journal of Bone and Joint Surgery, 1970, liver biopsy, but this is frequently ruled out by the prolonged 52A, 233. prothrombin time. There is variable but often intense fatty 7O'Brien, J. P., et al.,Journal of Bone and Joint Sturgery, 1971, 53B, 217. infiltration of the liver, with diffuse vacuolation of the hepa- 8 MacEwen, G. D., Bunnell, W. P., and Sriram, K., Jrournal of Bonie and Joint Suirgery, 1975, 57A, 404. tocytes without nuclear displacement and no hepatocellular 9 Ransford, A. O., and Manning, C. W. S. F.,3Journal of Bone andJoint Sur- necrosis.8 gery, 1975, 57B, 131. Since the diagnosis of is 1 Ponseti, I. V., and Friedman, B.,Jrournal of Bone andJoint Surgery, 1950, Reye's syndrome difficult its 32A, 381. incidence may be higher than is generally realized. About I James, J. I. P.,3Journal of Bone and Joint Surgery, 1951, 33B, 399. 400/,, of children diagnosed in life die.9 Features associated 12 James, J. I. P., Scoliosis. E. &. S. Livingstone, Edinburgh & London, 1967. 13 Nachemson, A., Acta Orthopaedica Scandinavica, 1968, 39, 466. with poor prognosis include a blood ammonia level higher 14 Nilsonne, U., and Lundgren, K-D., Acta Orthopaedica Scandinavica, than 200 tmol 1, a rapid progression to deep coma, a pro- 1968, 39, 456. -
Developmental Outcomes with Early Orthotopic Liver Transplantation For
Developmental Outcomes With Early Orthotopic Liver Transplantation for Infants With Neonatal-Onset Urea Cycle Defects and a Female Patient With Late-Onset Ornithine Transcarbamylase Deficiency Kim L. McBride, MD*; Geoffrey Miller, MD‡; Susan Carter, BSN*; Saul Karpen, MD, PhD‡; John Goss, MD§; and Brendan Lee, MD, PhD* ABSTRACT. Urea cycle defects (UCDs) typically nherited disorders of the urea cycle are character- present with hyperammonemia, the duration and peak ized by high ammonia levels and altered amino levels of which are directly related to the neurologic acid metabolism. There are 6 well-characterized outcome. Liver transplantation can cure the underlying I urea cycle defects (UCDs), ie, N-acetylyglutamate defect for some conditions, but the preexisting neuro- synthase, carbamoyl phosphate synthase (CPS), X- logic status is a major factor in the final outcome. Mul- linked ornithine transcarbamylase (OTC), arginosuc- ticenter data indicate that most of the children who re- cinate synthase, arginosuccinate lyase, and arginase ceive transplants remain significantly neurologically deficiencies. Arginase deficiency is not typical of the impaired. We wanted to determine whether aggressive other UCDs, because it presents not with hyperam- metabolic management of ammonia levels after early monemia but with spastic diplegia. Presentation of referral/transfer to a metabolism center and early liver transplantation would result in better neurologic out- the other UCDs can be quite variable, from cata- comes. We report on 5 children with UCDs, ie, 2 male strophic neonatal illness and acute episodic enceph- patients with X-linked ornithine transcarbamylase defi- alopathy in childhood or adulthood to chronic neu- 1 ciency and 2 male patients with carbamoyl phosphate rologic disorders. -
Carbamoyl Phosphate Synthetase I Deficiency
Carbamoyl phosphate synthetase I deficiency Description Carbamoyl phosphate synthetase I deficiency is an inherited disorder that causes ammonia to accumulate in the blood (hyperammonemia). Ammonia, which is formed when proteins are broken down in the body, is toxic if the levels become too high. The brain is especially sensitive to the effects of excess ammonia. In the first few days of life, infants with carbamoyl phosphate synthetase I deficiency typically exhibit the effects of hyperammonemia, which may include unusual sleepiness, poorly regulated breathing rate or body temperature, unwillingness to feed, vomiting after feeding, unusual body movements, seizures, or coma. Affected individuals who survive the newborn period may experience recurrence of these symptoms if diet is not carefully managed or if they experience infections or other stressors. They may also have delayed development and intellectual disability. In some people with carbamoyl phosphate synthetase I deficiency, signs and symptoms may be less severe and appear later in life. Frequency Carbamoyl phosphate synthetase I deficiency is a rare disorder; its overall incidence is unknown. Researchers in Japan have estimated that it occurs in 1 in 800,000 newborns in that country. Causes Mutations in the CPS1 gene cause carbamoyl phosphate synthetase I deficiency. The CPS1 gene provides instructions for making the enzyme carbamoyl phosphate synthetase I. This enzyme participates in the urea cycle, which is a sequence of biochemical reactions that occurs in liver cells. The urea cycle processes excess nitrogen, generated when protein is broken down by the body, to make a compound called urea that is excreted by the kidneys. The specific role of the carbamoyl phosphate synthetase I enzyme is to control the first step of the urea cycle, a reaction in which excess nitrogen compounds are incorporated into the cycle to be processed. -
Annual Summary of Communicable Disease Reported to MDH, 2003
MINNESOTA DEPARTMENT OF HEALTH DISEASE CONTROL N EWSLETTER Volume 32, Number 4 (pages 33-52) July/August 2004 Annual Summary of Communicable Diseases Reported to the Minnesota Department of Health, 2003 Introduction Minnesota Government Data Practices do not appear in Table 2 because the Assessment is a core public health Act (Section 13.38). Provisions of the influenza surveillance system is based function. Surveillance for communi- Health Insurance Portability and on reported outbreaks rather than on cable diseases is one type of ongoing Accountability Act (HIPAA) allow for individual cases. assessment activity. Epidemiologic routine communicable disease report- surveillance is the systematic collec- ing without patient authorization. Incidence rates in this report were tion, analysis, and dissemination of calculated using disease-specific health data for the planning, implemen- Since April 1995, MDH has participated numerator data collected by MDH and a tation, and evaluation of public health as one of the Emerging Infections standardized set of denominator data programs. The Minnesota Department Program (EIP) sites funded by the derived from U.S. Census data. of Health (MDH) collects disease Centers for Disease Control and Disease incidence may be categorized surveillance information on certain Prevention (CDC) and, through this as occurring within the seven-county communicable diseases for the program, has implemented active Twin Cities metropolitan area (Twin purposes of determining disease hospital- and laboratory-based surveil- Cities metropolitan area) or outside of it impact, assessing trends in disease lance for several conditions, including (Greater Minnesota). occurrence, characterizing affected selected invasive bacterial diseases populations, prioritizing disease control and food-borne diseases. Anaplasmosis efforts, and evaluating disease preven- Human anaplasmosis (HA) is the new tion strategies. -
Decreased Concentration of Xanthine Dehydrogenase (EC 1.1.1.204) in Rat Hepatomas1
[CANCER RESEARCH 46, 3838-3841, August 1986] Decreased Concentration of Xanthine Dehydrogenase (EC 1.1.1.204) in Rat Hepatomas1 Tadashi Ikegami, Yutaka Natsumeda, and George Weber2 Laboratory for Experimental Oncology, Indiana University School of Medicine, Indianapolis, Indiana 46223 ABSTRACT Immunodiffusion disc was from Miles Laboratories, Inc., Naperville, IL. All other chemicals were also of analytical grade. Xanthine dehydrogenase (EC 1.1.1.204), the rate-limiting enzyme of Tissues. Chemically induced transplantable hepatomas were main purine degradation, was purified 642-fold to homogeneity from liver of tained as described previously (9). Hepatoma 20 was transplanted in male Wistar rats. Antibody was generated to the purified enzyme in white male Buffalo strain rats, and hepatoma 3924A was carried in male rabbits and was partially purified. For the immunotitration a radioassay ACI/N rats. Livers from Buffalo and ACI/N rats were used as controls. of high sensitivity was developed to determine low enzyme activities. Hepatoma 3924A was homogenized with 3.3 volumes and hepatoma Titration curves with the antibody showed that the xanthine dehydrogen 20 and the livers were homogenized with 5 volumes of SOHIMpotassium ase enzyme protein amounts in slowly growing hepatoma 20 and rapidly phosphate buffer, pH 7.4, containing 0.25 M sucrose and 0.3 mM growing hepatoma 3924A were 34 and 4% of those of normal liver, which EDTA, respectively. The homogenates were centrifuged at 100,000 x was in good agreement with the decrease in the activity of the enzyme to g for 30 min, and the clear supernatants were used for the enzyme 33 and 2%, respectively. -
Cell and Gene Therapy for Carbamoyl Phosphate Synthetase 1 Deficiency
Journal of Pediatrics and Neonatal Care Cell and Gene Therapy for Carbamoyl Phosphate Synthetase 1 Deficiency Abstract Review Article Volume 7 Issue 1 - 2017 Carbamoyl phosphate synthetase 1 (CPS1) is the first and rate-limiting enzyme in the urea cycle. CPS1 deficiency is a devastating condition, which is clinically characterized by periodic episodes of life-threatening hyperammonemia. Currently, 1Associate at Department of Genetic Medicine, Children’s there is no cure for CPS1 deficiency except for liver transplantation, which is limited Research Institute, Children’s National Health System, USA on the progress to date, cell-based therapies—including hepatocyte or stem cell 2 by a severe shortage of donors and significant risk of mortality and morbidity. Based Washington Institute for Health Sciences, Department of transplantation—and new approaches for gene therapy have become the promising Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, USA curative treatments for CPS1 deficiency. This review outlines the current progress and *Corresponding author: Bin Li, MD, Washington Institute Keywords:challenges of cell and gene therapies for CPS1 deficiency. for Health Sciences, 4601 N Fairfax Drive, Arlington, VA therapy; Gene therapy 22203; Georgetown University Medical Center, 4000 Urea cycle defects; Carbamoyl phosphate synthetase 1 deficiency; Cell Reservoir Road, N.W., Washington D.C. 20057, United States. Tel: 202-687-6484, Fax: (202) 687-1800, Email: Abbreviations: AAVs: Adeno-Associated Viruses; -
Atypical Reye Syndrome
Acta Biomed 2021; Vol. 92, Supplement 1: e2021110 DOI: 10.23750/abm.v92iS1.10205 © Mattioli 1885 Case report Atypical Reye syndrome: three cases of a problem that pediatricians should consider and remember Serena Ferretti1, Antonio Gatto2, Antonietta Curatola1, Valeria Pansini2, Benedetta Graglia1, Antonio Chiaretti1,2 1 Department of Woman and Child Health and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy; 2 Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy Abstract. Introduction: Reye syndrome is a rare acquired metabolic disorder appearing almost always dur- ing childhood. Its etiopathogenesis, although controversial, is partially understood. The classical disease is typically anticipated by a viral infection with 3-5 days of well-being before the onset of symptoms, while the biochemical explanation of the clinical picture is a mitochondrial metabolism disorder, which leads to a metabolic failure of different tissues, especially the liver. Hypothetically, an atypical response to the preceding viral infection may cause the syndrome and host genetic factors and different exogenous agents, such as toxic substances and drugs, may play a critical role in this process. Reye syndrome occurs with vomiting, liver dys- function and acute encephalopathy, characterized by lack of inflammatory signs, but associated with increase of intracranial pressure and brain swelling. Moreover, renal, and cardiac dysfunction can occur. Metabolic acidosis is always detected, but diagnostic criteria are not specific. Therapeutic strategies are predominantly symptomatic, to manage the clinical and metabolic dysfunctions. Case reports: We describe three cases of chil- dren affected by Reye syndrome with some atypical features, characterized by no intake of potentially trigger substances, transient hematological changes and dissociation between hepatic metabolic impairment, severe electroencephalographic slowdown and slightly altered neurological examination. -
Raised Drug in Patient Recovered Completely Etiology Or Reye
upwards fixed gaze. The liver was enlarged and hypoglycemia and raised transaminases were noted. The encephalopathy and dystonic reactions were considered secondary to the anti-emetic drug in combination with liver disease most probably due to viral infection. Neurological examination was normal after 36 hours and the patient recovered completely after 10 days. The author stresses the need to consider drugs other than salicylates in the etiology or Reye syndrome and particularly the use anti-emetics (Casteels- VanDaele M. Reye syndrome or side effects of anti-emetics? Eur J Pediatr May 1991; 150:456-4591. COMMENT. In the 1960's several cases of toxic encephalopathy resembling Reye syndrome were reported in patients who had received the anti-emetic Tigan for vomiting. Dr. John Pepper, the Director of Toxicological Studies at Hoffman Laroche Company investigated these reports with customary thoroughness and with the aid of many consultants. No specific correlation between the use of Tigan and the toxic encephalopathy was determined. The lack of association of Reye syndrome with aspirin use has been reported from Australia (Orlowski J P et al. A catch in the Reye Pediatrics 1987; 80:638. See Ped Neur Briefs Nov 1987). HEADACHE CHOCOLATE IS A MIGRAINE-PROVOKING AGENT Patients with migraine who believe that chocolate could provoke their attacks were challenged with either chocolate or a closely matching placebo in a double-blind parallel group study at the Princess Margaret Migraine Clinic, Charing Cross Hospital, London, England. The placebo contained no cocoa butter or cocoa powder and the carob powder used in the placebo was also added to the chocolate and successfully disguised by the use of a peppermint- masking flavor. -
Influenza a Virus and Reye's Syndrome in Adults
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.43.6.516 on 1 June 1980. Downloaded from Journal of Neurology, Neurosurgery, and Psychiatry, 1980, 43, 516-521 Influenza A virus and Reye's syndrome in adults LARRY E DAVIS AND MARIO KORNFELD From the Neurology Service, Veterans Administration Medical Center and Department of Neurology and Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico S U M M A R Y We report fatal Reye's syndrome in two adults following proven influenza A viral infections. Reye's syndrome is, therefore, not confined to children but may also occur in adults. Many reported cases of postinfluenza A encephalopathy have clinical and pathological features of Reye's syndrome suggesting that they are not due to postinfectious perivenous demyelination. In 1963, Reye, Morgan, and Baral described 21 died. No one in his family had ever had illnesses children who, following a prodromal illness, suggesting abnormalities of the urea cycle. developed vomiting, seizures, coma and death.' Laboratory tests included a normal brain com- Noninflammatory cerebral oedema and fatty meta- puterised tomogram (CT), blood count, and serum morphosis of the liver was found at necropsy. An electrolytes. A traumatic lumbar puncture done Protected by copyright. increasing number of similar cases have since on admission had a normal opening pressure. The been reported worldwide. Reye's syndrome is gen- cerebrospinal fluid (CSF) contained 900 fresh red erally thought to occur only in children. The blood cells per mm3, 5 lymphocytes per mm3, 250 aetiology is unknown, but the syndrome has been mg per dl protein, 150 mg per dl glucose, and associated with epidemics of influenza B virus2 sterile bacterial and fungal cultures. -
Reye Syndrome
Number 84 January 2019 Reye Syndrome What is Reye Syndrome? Diarrhea and rapid breathing in infants and Reye Syndrome is a rare disease that mainly toddlers affects children and teenagers when they have, Persistent vomiting in children and teenagers or recently had, a viral infection such as Changes in personality or behaviour such as chickenpox or influenza. Reye Syndrome confusion, irritability or aggression. Reye causes swelling of the liver and brain, and it Syndrome may also cause strange behavior can also cause death. such as staring and slurred speech How can I prevent Reye Syndrome? Seizures and comas The use of acetylsalicylic acid (ASA or Loss of consciousness Aspirin®) has been strongly linked to Reye Syndrome. Do not give ASA or Aspirin® to Reye Syndrome occurs 3 to 7 days after the anyone under 18 years of age to manage beginning of an infection or illness caused by a symptoms such as fever, headache and muscle virus, or during recovery from the infection or aches. illness. Reye Syndrome can be misdiagnosed as swelling of the brain, also known as Instead, use acetaminophen for anyone under encephalitis or swelling of the lining of the 18 years of age. Examples of medications with brain (meningitis), diabetes, drug overdose, acetaminophen are Tylenol®, Tempra® and poisoning, sudden infant death syndrome Atasol®. (SIDS) or a psychiatric illness. You can also use ibuprofen for relief of What is the treatment? symptoms in children under 18 years of age. Early diagnosis and treatment in a hospital can Examples of ibuprofen include Advil® and save your child’s life.